---
document_datetime: 2023-09-21 17:16:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/invokana-epar-all-authorised-presentations_en.pdf
document_name: invokana-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3790945
conversion_datetime: 2025-12-19 23:45:25.046749
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EMA Number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

EU/1/13/884/001

EU/1/13/884/002

EU/1/13/884/003

Invokana

Invokana

Invokana

100 mg

100 mg

100 mg

Film-coated tablet

Film-coated tablet

Film-coated tablet

Oral use

Oral use

Oral use blister (PVC/Alu)

blister (PVC/Alu)

blister (PVC/Alu)

10 tablets

30 tablets

90 tablets

EU/1/13/884/004 Invokana 100 mg Film-coated tablet Oral use blister (PVC/Alu) 100 tablets

EU/1/13/884/005

EU/1/13/884/006

EU/1/13/884/007

EU/1/13/884/008

Invokana

Invokana

Invokana

Invokana

300 mg

300 mg

300 mg

300 mg

Film-coated tablet

Film-coated tablet

Film-coated tablet

Film-coated tablet

Oral use

Oral use

Oral use

Oral use blister (PVC/Alu)

blister (PVC/Alu)

blister (PVC/Alu)

blister (PVC/Alu)

10 tablets

30 tablets

90 tablets

100 tablets